KUALA LUMPUR, Sept 23 (Bernama) — Angelini Pharma, part of Angelini Industries, and Sovargen, a South Korean biotechnology company, have signed an exclusive global option agreement to co-develop and commercialise SVG105, an innovative brain health asset.
Under the terms of the agreement, Angelini Pharma and Sovargen will collaboratively lead the preclinical development efforts for SVG105, and, following an initial option period, Angelini Pharma will have the right to advance the compound into clinical development and commercialisation outside of the Republic of Korea, China, Hong Kong, Macau and Taiwan.
According to a statement, Sovargen will receive upfront and milestone payments totalling up to approximately US$550 million, as well as tiered royalties on post-approval net sales. (US$1=RM4.18)
“Neurological disorders like epilepsy remain a major global challenge, with many patients resistant to existing therapies.
“Our partnership with Sovargen aims to bring new hope to patients through innovative treatment options,” said Angelini Pharma chief executive officer (CEO), Jacopo Andreose.
Meanwhile, Sovargen CEO, Cheolwon Park added: “We are excited to leverage Angelini Pharma’s expertise to advance SVG105 toward transformative therapies for brain health.”
SVG105 is a potentially first-in-class antisense oligonucleotide designed to modulate mammalian target of rapamycin (mTOR), a genetically validated target for a number of brain health disorders, including drug-resistant childhood epilepsy.
This collaboration strengthens Angelini Pharma’s expanding brain health portfolio, which already includes partnerships and assets targeting rare genetic epilepsies, CNS disorders, and biologics crossing the blood-brain barrier.
Brain health disorders affect millions worldwide, carrying heavy social and economic burdens. Epilepsy alone impacts around 50 million people globally, with up to 40 per cent not achieving seizure control despite treatment.
This agreement underscores Angelini Pharma’s commitment to addressing unmet needs in neurological diseases through diversified and cutting-edge therapeutic modalities.
— BERNAMA
BERNAMA provides up-to-date authentic and comprehensive news and information which are disseminated via BERNAMA Wires; www.bernama.com; BERNAMA TV on Astro 502, unifi TV 631 and MYTV 121 channels and BERNAMA Radio on FM93.9 (Klang Valley), FM107.5 (Johor Bahru), FM107.9 (Kota Kinabalu) and FM100.9 (Kuching) frequencies.
Follow us on social media :
Facebook : @bernamaofficial, @bernamatv, @bernamaradio
Twitter : @bernama.com, @BernamaTV, @bernamaradio
Instagram : @bernamaofficial, @bernamatvofficial, @bernamaradioofficial
TikTok : @bernamaofficial
